1 Min Read
May 31(Reuters) - AmCad BioMed Corp
* Says it got marketing authorization in U.S. for its product AmCAD-US, which is used for early diagnosis of hepatic fibrosis
Source text in Chinese:goo.gl/1jHN6U
Further company coverage: (Beijing Headline News)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.